[PDF][PDF] The human cost of not achieving full remission in depression
RS McIntyre, C O'Donovan - Canadian Journal of Psychiatry, 2004 - Citeseer
Depression is among the most disabling and costly illnesses in the world. Despite good
short-term efficacy outcomes in the treatment of depression, long-term outcomes remain …
short-term efficacy outcomes in the treatment of depression, long-term outcomes remain …
Cost-utility analysis studies of depression management: a systematic review
PA Pirraglia, AB Rosen, RC Hermann… - American Journal of …, 2004 - Am Psychiatric Assoc
OBJECTIVE: Depression is common, costly, treatable, and a major influence on quality of
life. Cost-utility analysis combines costs with quantity and quality of life into a metric that is …
life. Cost-utility analysis combines costs with quantity and quality of life into a metric that is …
A clinical-and cost-effectiveness comparison of venlafaxine and selective serotonin reuptake inhibitors (SSRIs) in the management of patients with major depressive …
P Howard, C Knight - Journal of Medical Economics, 2004 - Taylor & Francis
This study evaluated the relative clinical-and cost-effectiveness of venlafaxine (Efectin®,
Wyeth Pharmaceuticals, Austria) extended release (ER), venlafaxine instant release (IR) …
Wyeth Pharmaceuticals, Austria) extended release (ER), venlafaxine instant release (IR) …
Pharmacoeconomic evaluations and primary care prescribing
O Wu - 2004 - theses.gla.ac.uk
This study aimed to investigate the effect of incorporating adverse drug reactions in
economic analyses of drug therapies. Subsequently, the impact of this information on …
economic analyses of drug therapies. Subsequently, the impact of this information on …